PD-L1 inhibitor

Efficacy of the Novel PD-L1 Inhibitor Socazolimab in Neoadjuvant Treatment Combined with Chemotherapy for Locally Advanced ESCC Requires Phase III Trial Validation

by
Efficacy of the Novel PD-L1 Inhibitor Socazolimab in Neoadjuvant Treatment Combined with Chemotherapy for Locally Advanced ESCC Requires Phase III Trial Validation

Click the blue text above“ioncology” to follow us, then click the “…” menu in the upper right corner and select “Set as Favorite”Neoadjuvant concurrent chemoradiotherapy remains the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Recent studies have also shown survival advantages from neoadjuvant chemotherapy alone, but the improvement in pathological complete response … Read more

Efficacy of the Novel PD-L1 Inhibitor Socazolimab in Neoadjuvant Treatment Combined with Chemotherapy for Locally Advanced ESCC Requires Phase III Trial Validation

by
Efficacy of the Novel PD-L1 Inhibitor Socazolimab in Neoadjuvant Treatment Combined with Chemotherapy for Locally Advanced ESCC Requires Phase III Trial Validation

Click the blue text above“ioncologyGI” to follow us, then click the “…” menu in the upper right corner and select “Set as Favorite”Neoadjuvant concurrent chemoradiotherapy remains the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Recent studies have also shown survival advantages from neoadjuvant chemotherapy alone, but the improvement in pathological complete response … Read more